Maybe some of this isn't coincidental at all. The address change, Mr. Barker's new shares, and the IP firm change all taken together could easily imply something big is coming soon. Some last minute rewards for BOD. Address change may be to facilitate a temporary co-location with an acquiring organization. And can anyone find out if Merchant & Gould already represent any large surgical companies with an interest in robotics? It would be a lot easier, cleaner, and cheaper to handle the transfer of patent assignments within one organization.
Speaking of patents, there was a little company with a patent portfolio of similar size to Titan's, maybe a little smaller. Anyone remember Auris? They were FDA approved, with a device that had much more limited indications than Titan's eventual targets. JnJ paid $3.4B up front with another almost $2.5B to meet additional milestones. A bit shy of $6B total for Auris.
Folks thinking Titan would be bought for 80 cents a share? Does that make any sense in this real world which is currently in a frenzy to release new robotic surgery technology into the marketplace? Let's say for the sake of argument that our current OS is 50M; that should easily represent a worst case scenario right now. At 80 cents, someone would scoop Titan for $40M. Why would anyone here truly believe that Titan would be bought for 1/150th of what the limited-scope Auris sold for a year ago? Is there any actual logic that could substantiate this? I don't see it.
Could we go for $6B like Auris? I don't see it happening without CE Mark and FDA approval. But a system that is less than $100M from the finish line, with a rich patent portfolio and rave reviews from everyone who has tried it - and is capable of retailing for one third less than the only current single port competition - $2B would still be a raging bargain for an acquirer. Why should $1B or $1.5B not be feasible?
Message in reply to:
JMAC13 Tuesday, 02/04/20 07:49:16 PM
Re: Honeycomb777 post# 103244 0
Post # 103279 of 103292
All this patent/trademark talk had me dive back into the patents for Titan Medical (not ENOS) saw something odd. A lot of activity last month 12/17/19 (pretty recent) including a “change of owner address” as well as Titan is now using Merchant & Gould as their IP firm. Seems this firm handles M&A’ s and they are based in Minneapolis. Merchant & Gould’s largest account is Microsoft. All this activity and crickets from the Knobbe enos side. Why leave that dormant and not address when doing all this other USPTO stuff? Christopher Stanton is the new attorney in the correspondence for Merchant & Gould.
Please forgive me if this has already been discussed and this is already known. Just thought when looking at the transaction history on the patent that this recent “change of owner address” stuck out as odd. They use these when doing a M&A it’s called an “Assignment” One last small thing that I noticed from the website is that Titan has already updated toe copyright at the bottom to 2020. One month in the new year. Titan notoriously has the copyright fall behind. It takes them forever to do anything. Why are they so on point with this? We all know how long it takes them to ANYTHING. yet this is done just over a month into the new year. What are they preparing for. Why is this a top priority now.
